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Abstract 
Bladder cancer usually spreads via the lymphatic and hematogenous routes, the most 
common sites of metastases of urinary bladder cancers being the regional lymph nodes, 
liver, lung, bone, peritoneum, pleura, kidney, adrenal gland and intestines. Generalized 
lymph node metastasis of transitional cell cancer of the bladder is extremely rare. 
According to our literature search, there has been no case report of transitional cell 
cancer of the bladder that manifests as an extensive large lymph node metastasis 
involving the intraparotid, supraclavicular thoracic inlet, axillary and regional abdominal 
and pelvic lymph nodes without bone or visceral organs involved. Such a presentation 
could be mistaken as malignant lymphoma and the importance of a biopsy of the lymph 
nodes is emphasized. The clinical course of rapid progression of the disease and the 
presence of wild-type p53 with rapid response to chemotherapy and a short remission 
may represent a unique case, which is discussed here. 
 
Introduction 
Urinary bladder cancer (UBC) is the 4th and 9th most frequent cancer diagnosed in 
men and women, respectively, in the United States. It was estimated that 70,980 new cases 
of UBC and 14,330 related deaths would occur in the United States in 2009 [1]. 
The presence of microscopic or macroscopic metastases at diagnosis is responsible for 
the incurability of invasive urothelial cancer [2]. Lymph node metastases are found in 20  
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to 25% of patients with UBC, mainly in the external and internal iliac and the obturator 
sites as the primary lymphatic drainage of the bladder and the common iliac sites as the 
secondary drainage. These are the most common lymph nodes involved with metastatic 
UBC [12]. However, generalized lymph node metastasis, with involvement of the lymph 
nodes above the diaphragm, mimicking an aggressive lymphoma in UBC, is extremely 
rare. To the best of our knowledge, this is the first case of advanced urinary bladder 
carcinoma presenting as a lymphoma-like picture with extensive lymph nodes 
involvement and without any bony or visceral metastasis. 
Case Report 
In April 2008, a 58-year-old Caucasian male with a past medical history of hypertension was 
admitted to our institute with a one-month history of hematuria. His social history was relevant for 
having smoked one pack per day for 20 years, which he stopped about 15 years ago, and consuming a 
moderate amount of alcohol. He had hadnumerous tattoos on his body when he was young. Family 
history included his mother having had a urinary bladder carcinoma at age 70. He initially underwent 
cystoscopy, during which he was noted to have a bladder mass. Therefore, transurethral resection of 
bladder tumor was performed. The pathologic examination of the mass revealed high-grade (3/3) 
transitional cell carcinoma (TCC) with invasion to the lamina propria, but not to the muscularis 
propria. He was then treated with intramucosal Bacillus Calmette-Guérin therapy. A follow-up 
cystoscopy in August 2009 revealed evidence of recurrence. Therefore, imaging studies were obtained. A 
computed tomography scan of the abdomen and pelvis showed an abnormally thick and nodular 
bladder wall with diffuse infiltration of the prevesical fat, consistent with recurrent bladder tumor with 
multiple enlarged retroperitoneal, bilateral common iliac, external iliac obturator, and femoral lymph 
nodes which were not noted in the prior studies (fig. 1). Biopsies of the bladder mass and pelvic lymph 
nodes were obtained. Pathologic examination of the samples confirmed recurrent urothelial carcinoma, 
which was further supported by immunohistochemical staining (fig. 2). During the one-month interval 
in which the patient was being prepared for further treatment he was found to have generalized multiple 
lymphadenopathy in cervical and axillary regions bilaterally, which were more prominent on the left 
side (fig. 3). In addition, he had multiple enlarged left supraclavicular and left axillary lymph nodes. A 
PET scan was obtained, which demonstrated focal hypermetabolic uptake in multiple lymph nodes, 
including the intraparotid, supraclavicular, left thoracic inlet, left axillary, right retrocrural, 
peripancreatic, aortocaval, left paraaortic, and bilateral external iliac chain, which was suggestive of 
malignant lymphoma. There was no other visceral or bony metastatic disease. HIV and hepatitis 
serologic testing was negative. Biopsy of the cervical lymph nodes was done to rule out lymphoma and 
the pathology was consistent with metastatic urothelial carcinoma with negative marker for CD45 (fig. 
4). The sample was examined for the p53 gene mutation, which was negative. In a short period of time 
the patient developed severe jaundice with a total bilirubin level of 26 ng/ml. An MRI cholangiogram 
was done, which showed obstruction of the common bile duct most likely secondary to impingement by 
lymph node metastasis. In view of the rapid progression of the disease, combination chemotherapy with 
100 mg/m
2 cisplatin on day 1, and 1,000 mg/m
2 gemcitabine on days 1 and 8, every 21 days, with a 50% 
dose reduction of gemcitabine because of high serum bilirubin levels, was started. After one cycle of 
chemotherapy, the jaundice had decreased considerably. Moreover, the cervical lymphadenopathy was 
barely palpable. There was also a significant decrease in the perivesical and pelvic lymphadenopathy. 
After the 2nd cycle of chemotherapy on regular follow up we noted that the patient had acute renal 
failure with a significantly decreased kidney function. Imaging studies did not show any external 
obstruction, so a cystoscopy was performed and an apparent carcinoma of the urinary bladder was 
observed. Bilateral urethral stents were placed, which improved the kidney function. Repeat imaging 
studies showed bilateral pulmonary lesions suspicious of metastasis but the pelvic and cervical 
lymphadenopathy had markedly decreased. The chemotherapy was changed to carboplatin plus 
paclitaxel but the patient developed diplopia. An MRI of the head was done which showed metastasis to 
the putamen, for which the patient received radiation therapy. The patient expired suddenly after he 
had collapsed at home. Autopsy was not obtained.  
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Discussion 
The lymph node drainage from the superior part of the bladder passes to the external 
iliac lymph nodes, and those from the inferior part of the bladder pass to the internal iliac 
nodes. Some lymphatic vessels from the neck region of the bladder drain into the sacral or 
common iliac lymph nodes. In a report of 107 patients, the most common site of 
metastasis of UBC was the regional lymph nodes (78%). Other common sites include the 
liver (38%), lung (36%), bone (27%), adrenal gland (21%), and intestine (13%) [2]. Many 
unusual sites of metastatic UBC have also been reported. In the same series, Babaian et al. 
reported metastases in the heart, brain, kidney, spleen, pancreas, meninges, uterus, ovary, 
prostate, and testes in 1 to 8% of their patients [2]. The pattern of recurrence and 
metastases are not dependent on the features of the primary tumor [3]. There is no 
difference in the frequency and location of metastasis between TCC and squamous cell 
carcinoma of the bladder. The frequency of metastases increases with local tumor 
extension [4]. Metastases of urothelial bladder cancer to the head and neck area and 
cervical or axillary lymph node sites occur in a very low rate, according to a retrospective 
autopsy study [5]. Hessan et al. retrospectively reviewed 845 cases of urogenital tract 
tumors for metastases to the head and neck area lymph nodes. Of 207 patients with 
metastasis, only 3 cases had metastasis with UBC in origin [6]. There are no reported 
cases of UBC with extensive lymph node involvement without any bone or other visceral 
organs involved, in which cases may be mistaken for malignant lymphoma. The present 
case demonstrates that TCC can rarely manifest as a lymphoma-like picture, and 
emphasizes again that a biopsy of lymph nodes is necessary to confirm the histology 
diagnosis. 
Systemic cisplatin-based chemotherapy is the standard approach for patients with 
inoperable, locally advanced or metastatic disease, with average response rates of 
approximately 50–60% [7]. Advanced TCC of bladder is moderately sensitive to cisplatin-
based combination chemotherapy; a variety of drugs are shown to have activity. 
Combination chemotherapy in patients with metastatic disease achieves 0–35% complete 
response and an overall response rate of 12–73% [8]. Gemcitabine plus cisplatin is equally 
effective and less toxic than methotrexate, vinblastin, Adriamycin, and cisplatin (MVAC). 
For patients not suitable for cisplatin-containing regimens, carboplatin-based regimens or 
gemcitabine plus taxanes can be substituted [9]. 
Mutation of p53, a well-characterized tumor suppressor gene which is located on 
chromosome 17p13.1, is one of the most common genetic events in urothelial tumors. 
There appears to be an association between p53 expression of the primary tumor and the 
stage and grade of the tumor, and lymph node metastasis. p53-stain negative tumors are 
more likely to be organ-confined and of lower grade [10], while overexpression of mutant 
p53 protein is generally associated with poorly differentiated invasive bladder tumors 
[11]. The presence of wild type p53 and the rapid progression of disease in this patient 
remain unexplained. A lymphoma-like presentation may suggest rapid progression of this 
type of aggressive UBC. The rapid response to chemotherapy may be related to the wild 
type of p53. A short duration of response to cisplatin chemotherapy and rapid 
progression of the presented case may be related to this unique type of carcinoma of the 
urinary bladder presenting as a malignant lymphoma-like picture. 
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Fig. 1. Contrast-enhanced computed tomography scan demonstrating thickening of left lateral bladder 
wall, enlarged pelvic lymph nodes and perivesical lymph nodes before chemotherapy. 
 
 
 
Fig. 2. Core biopsy of left pelvic lymph node demonstrating lymphoid tissue with infiltration of 
malignant cells, consistent with metastatic urothelial carcinoma on immunohistochemical tumor 
analysis. 
 
 
 
Fig. 3. Contrast-enhanced computed tomography scan demonstrating bilateral cervical lymph nodes 
before chemotherapy; the left side is more enlarged than the right. 
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Fig. 4. Core biopsy of left cervical lymph node demonstrating fibrous tissue with infiltration of 
malignant cells, consistent with urothelial carcinoma confirmed by immunohistochemical tumor 
analysis. 
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